Vaxart Inc

NASDAQ: VXRT    
Share price (4/25/24): $0.66    
Market cap (4/25/24): $116 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.59
from 10-K 77 pages Part I – The Schedule Section B – Supplies or Services and Prices/Costs B.1. Brief Description of Services
12/34/56
EX-10.1
from 8-K 4 pages February 21, 2024 Steven Lo via Email Re: Offer of Employment Salary, Bonus Rate and Benefits
12/34/56
EX-10.3
from 8-K 13 pages Vaxart, Inc. Stock Option Grant Notice
12/34/56
EX-10.2
from 8-K 11 pages Vaxart, Inc. Restricted Stock Unit Grant Notice
12/34/56
EX-10.1
from 8-K 18 pages Vaxart, Inc. 2024 Inducement Award Plan Adopted by the Board of Directors: February 27, 2024
12/34/56
EX-10.1
from 8-K/A 15 pages Specific Terms in This Exhibit Have Been Redacted Because Disclosure of Such Information Would Constitute a Clearly Unwarranted Invasion of Personal Privacy. These Redacted Terms Have Been Marked in This Exhibit With Three Asterisks: [***] Separation Agreement
12/34/56
EX-10.1
from 8-K 17 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 4 pages January 16, 2024 on Behalf of Vaxart, Inc. (The “Company”), I Am Pleased to Provide You With This Letter Agreement (This “Agreement”) Setting Forth the Terms and Conditions of Your Employment as President and Chief Executive Officer (“CEO”) of the Company, Effective as of January 16, 2024 (The “Effective Date”)
12/34/56
EX-10.2
from 10-Q 1 page Amendment to the Vaxart, Inc. Severance Benefit Plan
12/34/56
EX-10.1
from 10-Q 2 pages Material contract
12/34/56
EX-10.53
from 10-K 3 pages Certain Information Contained in This Document, Marked by “[***]”, Has Been Omitted Because It Constitutes a Clearly Unwarranted Invasion of Personal Privacy
12/34/56
EX-10.4
from 10-Q 7 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Both (I) Is Not Material and (II) Is the Type of Information the Issuer Both Customarily and Actually Treats as Private and Confidential. Such Excluded Information Has Been Marked With “[***]” Pre-Challenge Study Services Agreement
12/34/56
EX-10.2
from 8-K/A 11 pages 2022 Employee Stock Purchase Plan
12/34/56
EX-10.1
from 8-K/A 21 pages Vaxart, Inc. 2019 Equity Incentive Plan Adopted by the Board of Directors: February 26, 2019 Approved by the Stockholders: April 23, 2019 1st Amendment Approved by the Stockholders: June 8, 2020 2nd Amendment Approved by the Stockholders: June 16, 2021 3rd Amendment Approved by the Stockholders: August 4, 2022
12/34/56
EX-10.2
from 8-K 3 pages Consulting Services Agreement
12/34/56
EX-10.1
from 8-K 5 pages Confidential Consulting Agreement
12/34/56
EX-10.2
from 10-Q 2 pages Vaxart, Inc. Non-Employee Director Compensation Program
12/34/56
EX-10.46
from 10-K 5 pages January 18, 2022 Re: Offer of Employment Salary, Bonus Rate and Benefits
12/34/56
EX-10.45
from 10-K 52 pages Asset Purchase Agreement by and Between Vaxart, Inc. and Kindred Biosciences, Inc. November 24, 2021
12/34/56
EX-10.4
from 10-Q 4 pages August 16, 2021 Re: Offer of Employment Dear James,
12/34/56